Fig. 2: Progression-free survival and overall survival. | British Journal of Cancer

Fig. 2: Progression-free survival and overall survival.

From: Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

Fig. 2: Progression-free survival and overall survival.The alternative text for this image may have been generated using AI.

a Progression-free survival. b Overall survival. *Patients with non-ovarian gynaecological cancers (endometrial cancer or cancer of the cervix) and patients with tumours known to be mismatch repair deficient or HRD that are not eligible for inclusion in any other arms of the trial but that may be expected to benefit from the PARP/PD-1 inhibitor combination (see Supplementary Table S1 for the full list of cancer types enrolled in this arm). Data cutoff: 25 September 2020. BRCAmut breast cancer type 1/2 susceptibility gene mutation, BRCAwt breast cancer type 1/2 susceptibility gene wildtype, EOC epithelial ovarian cancer, G/GEJ gastric or gastroesophageal junction, HER2− HER2 negative, HRD homologous recombination deficiency, HRP homologous recombination proficiency, mCRPC metastatic castration-resistant prostate cancer, OS overall survival, PD-1 programmed cell death protein 1, PFS progression-free survival, SCLC small cell lung cancer, TNBC triple-negative breast cancer.

Back to article page